RWJ Health Connect | Patient PortalGo
  • 1-888-MD-RWJUH
  • YouTube

RWJUH Director of Transradial Catheterization is First N.J. Physician Certified to Use Less Invasive Coronary Artery Disease Treatment

Diamondback 360® Coronary Orbital Atherectomy Device Recently Approved by FDA

April 10, 2014
NEW BRUNSWICK, N.J. - Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital (RWJUH) offers a new alternative to open up blocked arteries.
Plaque build-up in the arteries can form calcium lesions, and that build-up can be difficult to treat and significantly impact the quality of life of persons affected, explains Ramzan M. Zakir M.D., Clinical Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School and Director of Transradial Catheterization at RWJUH. For patients with lots of calcium in the arteries, it may be necessary to break up the calcium to allow the stents to open up or expand properly, he adds.
“Although a device to break up calcium exists, that same device hasn’t really changed in over 20 years. It’s complex to use and involves a lengthy set-up time, leading some physicians to opt for open heart surgery to treat such blockages,” he says. “With the recently FDA-approved device called the Diamondback 360, we can easily break up the calcium to facilitate stent delivery and proper expansion. Even complex cases that previously could only be treated through the femoral artery now can be treated radially to restore proper blood flow and relieve patients’ symptoms such as chest pain and shortness of breath.”
Zakir has completed the required training, including six cases, for use of the Diamondback 360® Coronary Orbital Atherectomy System and is now the first physician in New Jersey to receive coronary certification from device maker Cardiovascular Systems, Inc. (CSI).
This new, less invasive treatment alternative is significantly important for patients with severely calcified coronary artery disease that are considered high risk, including those managing other diseases (such as diabetes and chronic kidney disease) or the elderly, Zakir says.
CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. CAD is a life-threatening condition and leading cause of death in men and women in the United States.
The risk of CAD increases if a person has one or more of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. CAD affects an estimated 17 million people in the United States and is the most common form of heart disease, which claims more than 600,000 lives in the United States each year.
According to estimates, significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention (PCI). Significant calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and major adverse cardiac events.
Cardiovascular Systems, Inc. received FDA approval for the Diamondback 360 in October and RWJUH is one of only two hospitals in New Jersey using it.
Reporters interested in arranging an interview with Dr. Zakir should contact RWJUH Public Relations at (732) 937-8521.

About Robert Wood Johnson University Hospital

Robert Wood Johnson University Hospital (RWJUH) is a 965-bed academic medical center with campuses in New Brunswick and Somerville, NJ.  Its Centers of Excellence include cardiovascular care from minimally invasive heart surgery to transplantation, cancer care, stroke care, neuroscience, joint replacement, and women’s and children’s care including The Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital ( 

As the flagship Cancer Hospital of Rutgers Cancer Institute of New Jersey and the principal teaching hospital of Rutgers Robert Wood Johnson Medical School in New Brunswick, RWJUH is an innovative leader in advancing state-of-the-art care. A Level 1 Trauma Center and the first Pediatric Trauma Center in the state, RWJUH’s New Brunswick campus serves as a national resource in its ground-breaking approaches to emergency preparedness.

RWJUH has been ranked among the best hospitals in America by U.S. News & World Report seven times and has been selected by the publication as a high performing hospital in numerous specialties.  The Bristol-Myers Squibb Children’s Hospital has been ranked among the best hospitals in America by U.S. News & World Report three times. In addition, RWJUH was named among the best places to work in health care by Modern Healthcare magazine and received the Equity Care of Award as Top Hospital for Healthcare Diversity and Inclusion from the American Hospital Association.

Both the New Brunswick and Somerset campuses have earned significant national recognition for clinical quality and patient safety, including the prestigious Magnet® Award for Nursing Excellence and “Most Wired” designation by Hospitals and Health Networks Magazine. The Joint Commission and the New Jersey Department of Health and Senior Services have designated the New Brunswick Campus as a Comprehensive Stroke Center and the Somerset Campus as a Primary Stroke Center.

The American College of Surgeons’ Commission on Cancer has rated RWJUH New Brunswick among the nation’s best comprehensive cancer centers and designated the Steeplechase Cancer Center at RWJ Somerset as a Comprehensive Community Cancer Center.  The Joint Surgery Center at Robert Wood Johnson University Hospital Somerset has earned the Joint Commission’s Gold Seal of Approval for total knee and total hip replacement surgery.